Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Papillary Thyroid Cancer-Pipeline Review, H1 2015

Papillary Thyroid Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Papillary Thyroid Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Papillary Thyroid Cancer-Pipeline Review, H1 2015', provides an overview of the Papillary Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Papillary Thyroid Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Papillary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Papillary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Papillary Thyroid Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Papillary Thyroid Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Papillary Thyroid Cancer Overview 7

Therapeutics Development 8

Pipeline Products for Papillary Thyroid Cancer-Overview 8

Pipeline Products for Papillary Thyroid Cancer-Comparative Analysis 9

Papillary Thyroid Cancer-Therapeutics under Development by Companies 10

Papillary Thyroid Cancer-Therapeutics under Investigation by Universities/Institutes 11

Papillary Thyroid Cancer-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Papillary Thyroid Cancer-Products under Development by Companies 15

Papillary Thyroid Cancer-Products under Investigation by Universities/Institutes 16

Papillary Thyroid Cancer-Companies Involved in Therapeutics Development 17

AstraZeneca PLC 17

Eisai Co., Ltd. 18

Exelixis, Inc. 19

Ignyta, Inc. 20

Novartis AG 21

Pfizer Inc. 22

Plexxikon Inc. 23

Vaccinex, Inc. 24

Papillary Thyroid Cancer-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

cabozantinib s-malate-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

CLM-29-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

CLM-3-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

dabrafenib mesylate-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

entrectinib-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

everolimus-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

lenvatinib-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

pasireotide-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

PLX-7486-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

PLX-8394-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

sunitinib malate-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

vandetanib-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

VX-15-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Papillary Thyroid Cancer-Recent Pipeline Updates 71

Papillary Thyroid Cancer-Dormant Projects 100

Papillary Thyroid Cancer-Discontinued Products 101

Papillary Thyroid Cancer-Product Development Milestones 102

Featured News & Press Releases 102

May 06, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains European Orphan Drug Status 102

Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 102

Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 102

Appendix 104

Methodology 104

Coverage 104

Secondary Research 104

Primary Research 104

Expert Panel Validation 104

Contact Us 104

Disclaimer 105

List of Tables

Number of Products under Development for Papillary Thyroid Cancer, H1 2015 8

Number of Products under Development for Papillary Thyroid Cancer-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Papillary Thyroid Cancer-Pipeline by AstraZeneca PLC, H1 2015 17

Papillary Thyroid Cancer-Pipeline by Eisai Co., Ltd., H1 2015 18

Papillary Thyroid Cancer-Pipeline by Exelixis, Inc., H1 2015 19

Papillary Thyroid Cancer-Pipeline by Ignyta, Inc., H1 2015 20

Papillary Thyroid Cancer-Pipeline by Novartis AG, H1 2015 21

Papillary Thyroid Cancer-Pipeline by Pfizer Inc., H1 2015 22

Papillary Thyroid Cancer-Pipeline by Plexxikon Inc., H1 2015 23

Papillary Thyroid Cancer-Pipeline by Vaccinex, Inc., H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 27

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 34

Papillary Thyroid Cancer Therapeutics-Recent Pipeline Updates, H1 2015 71

Papillary Thyroid Cancer-Dormant Projects, H1 2015 100

Papillary Thyroid Cancer-Discontinued Products, H1 2015 101

List of Figures

Number of Products under Development for Papillary Thyroid Cancer, H1 2015 8

Number of Products under Development for Papillary Thyroid Cancer-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 26

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Top 10 Molecule Types, H1 2015 33

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AstraZeneca PLC

Eisai Co., Ltd.

Exelixis, Inc.

Ignyta, Inc.

Novartis AG

Pfizer Inc.

Plexxikon Inc.

Vaccinex, Inc.

Papillary Thyroid Cancer Therapeutic Products under Development, Key Players in Papillary Thyroid Cancer Therapeutics, Papillary Thyroid Cancer Pipeline Overview, Papillary Thyroid Cancer Pipeline, Papillary Thyroid Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com